Literature DB >> 23810364

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

Jonathan W Riess1, Sukhmani K Padda, Charles D Bangs, Millie Das, Joel W Neal, Adour R Adrouny, Athena Cherry, Heather A Wakelee.   

Abstract

Entities:  

Keywords:  Chemotherapy; Molecular subtypes; NSCLC; Pemetrexed; ROS1

Mesh：

Substances：

Year:  2013        PMID： 23810364      PMCID： PMC4156821          DOI： 10.1016/j.cllc.2013.04.008

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  10 in total

1.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

2.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

3.  Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Authors:  Jeong-Ok Lee; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Soyeon Kim; Yoon-Kyung Jeon; Doo Hyun Chung; Woo-Ho Kim; Young Tae Kim; Seok-Chul Yang; Young Whan Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

4.  Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

Authors:  D Ross Camidge; Scott A Kono; Xian Lu; Sonia Okuyama; Anna E Barón; Ana B Oton; Angela M Davies; Marileila Varella-Garcia; Wilbur Franklin; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

5.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

6.  Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

Authors:  A T Shaw; A M Varghese; B J Solomon; D B Costa; S Novello; M Mino-Kenudson; M M Awad; J A Engelman; G J Riely; V Monica; B Y Yeap; G V Scagliotti
Journal:  Ann Oncol       Date:  2012-08-10       Impact factor: 32.976

7.  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors:  Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2012-08-23       Impact factor: 12.531

8.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

Authors:  Giorgio Scagliotti; Nasser Hanna; Frank Fossella; Katherine Sugarman; Johannes Blatter; Patrick Peterson; Lorinda Simms; Frances A Shepherd
Journal:  Oncologist       Date:  2009-02-16

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582
  10 in total
  14 in total

1.  AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

Authors:  Terry L Ng; D Ross Camidge
Journal:  Ann Transl Med       Date:  2017-05

Review 2.  Recent Advances in Targeting ROS1 in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-08-14       Impact factor: 15.609

Review 3.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

Review 4.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

5.  Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site.

Authors:  Tindara Franchina; Alessandro Russo; Giuseppina Rosaria Ricciardi; Giuseppina Liguori; Astrid Herberg; Nicola Normanno; Vincenzo Adamo
Journal:  Cancer Biol Ther       Date:  2016-09-10       Impact factor: 4.742

6.  Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.

Authors:  Shafei Wu; Jinghui Wang; Lijuan Zhou; Dan Su; Yuanyuan Liu; Xiaolong Liang; Shucai Zhang; Xuan Zeng
Journal:  Thorac Cancer       Date:  2015-07-02       Impact factor: 3.500

7.  Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.

Authors:  Ying Liang; Heather A Wakelee; Joel W Neal
Journal:  Clin Lung Cancer       Date:  2014-12-31       Impact factor: 4.785

8.  Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.

Authors:  Limin Zhang; Tao Jiang; Chao Zhao; Wei Li; Xuefei Li; Sha Zhao; Xiaozhen Liu; Yijun Jia; Hui Yang; Shengxiang Ren; Caicun Zhou
Journal:  Oncotarget       Date:  2016-11-15

9.  Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.

Authors:  Liang Dong; Jingwen Xia; Jing Zhang; Yuanyuan Zhang; Ning Zhu; Peng Zhang; Youzhi Zhang; Xiujuan Zhang; Shengqing Li
Journal:  BMC Pulm Med       Date:  2018-01-23       Impact factor: 3.317

10.  Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.

Authors:  Zhengbo Song; Haiyan Su; Yiping Zhang
Journal:  Cancer Med       Date:  2016-08-20       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.